Internal Medicine, Rheumatology · San Juan, PR
NPI
1497952584
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
Medical Pavilion Suite 5, Calle San Rafael 1396
San Juan, PR, 00910
Phone (787) 725-6713
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$6.0M
6,539 prescriptions
Company payments, 2025
$5,679
From 16 companies
Medicare prescription drug claims, 2024
In 2024, the drug Karina Vila-Rivera prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 662 prescriptions and refills. In total Karina Vila-Rivera wrote 6,539 Medicare prescriptions that cost $6.0M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-01-16.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Methotrexate Methotrexate Sodium | 662 | 671 | 102 | $7,951 |
| Hydroxychloroquine Sulfate Generic | 546 | 564 | 95 | $17K |
| Gabapentin Generic | 502 | 542 | 80 | $3,367 |
| Duloxetine Hcl Generic | 285 | 299 | 56 | $3,389 |
| Prednisone Generic | 245 | 253 | 51 | $1,360 |
| Pregabalin Generic | 245 | 247 | 38 | $5,358 |
| Humira(Cf) Pen Adalimumab | 164 | 168 | 16 | $1.5M |
| Rinvoq Upadacitinib | 157 | 157 | 18 | $1.0M |
| Mycophenolate Mofetil Generic | 127 | 142 | 21 | $5,841 |
| Diclofenac Sodium Er Diclofenac Sodium | 125 | 125 | 31 | $6,073 |
| Allopurinol Generic | 103 | 121 | 15 | $675 |
| Synthroid Levothyroxine Sodium | 97 | 123 | 24 | $5,958 |
| Xeljanz Xr Tofacitinib Citrate | 97 | 97 | 12 | $560K |
| Nabumetone Generic | 96 | 96 | 33 | $1,176 |
| Orphenadrine Citrate Er Orphenadrine Citrate | 92 | 92 | 37 | $2,557 |
Brand drugs: - claims; generic drugs: 5,084 claims; opioid claims: 32.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Karina Vila-Rivera $5,679 ($3,255 in general payments such as food, travel and fees and $2,423 for research) from 16 companies. The largest payer was Sanofi US Services Inc. with $2,423.
| Company | Payments | Amount |
|---|---|---|
| Sanofi US Services Inc. SNY | 9 | $2,423 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 14 | $1,841 |
| Amgen Inc. AMGN | 14 | $535 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $253 |
| Abbvie Inc. ABBV | 5 | $214 |
| GlaxoSmithKline, LLC. GSK | 2 | $141 |
| ANI Pharmaceuticals, Inc. ANIP | 6 | $113 |
| Mallinckrodt Hospital Products Inc. | 1 | $84.99 |
| Organon LLC OGN | 1 | $24.08 |
| Novo Nordisk Inc NVO | 1 | $17.47 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.